Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders

• US 20030147858A1
• Filed: 02/06/2003
• Published: 08/07/2003
• Est. Priority Date: 05/11/2000
• Status: Active Grant

• Current Assignee: Armistice Capital Master Fund Ltd. (Armistice Capital LLC), CJ Bioscience Incorporated
• Original Assignee: Institut National de La Recherche Agronomique
• Inventors: Renaud, Michel, Bernalier, Annick
• Granted Patent: US 7,749,494 B2
• Time in Patent Office: Days
• US Class Current: 424/93.4
• CPC Class Codes: A61K 35/742 Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: Y10S 435/822 using bacteria or actinomycetales

Abstract

The invention concerns the use of non-pathogenic hydrogenotrophic acetogenic bacterial strains for preparing a composition for treating or preventing gastrointestinal disorders associated with productions of digestive gases and/or for modulating the microbial balance of the digestive ecosystem in a mammal. The invention also concerns said pharmaceutical or food compositions, and the methods for monitoring and preparing said strains.

Claims

1. The use of at least one nonpathogenic, hydrogenotrophic, acetogenic bacterial strain for preparing a composition for treating or preventing gastrointestinal disorders, and/or for modulating the microbial balance of the digestive ecosystem in a mammal.

2. The use according to claim 1, characterized in that the gastrointestinal disorders are included in the group comprising a) functional colopathies, characterized by excessive flatulence, meteorism, bloating or abdominal pain, irritable bowel syndrome, and b) ulcerative colitis, inflammatory bowel diseases and Crohn'"'"'s disease.

3. The use according to claim 1 or 2, characterized in that the at least one nonpathogenic, hydrogenotrophic, acetogenic bacterial strain is an autologous strain of said mammal.

4. The use according to any one of claims 1 to 3, characterized in that the at least one nonpathogenic, hydrogenotrophic, acetogenic bacterial strain is viable in the digestive tract.

5. The use according to any one of claims 1 to 4, characterized in that the at least one nonpathogenic, hydrogenotrophic, acetogenic bacterial strain belongs to the Ruminococcus, Clostridium or Streptococcus genus.

6. The use according to claim 5, characterized in that the at least one nonpathogenic, hydrogenotrophic, acetogenic bacterial strain belongs to the species Ruminococcus hydrogenotrophicus.

7. The use according to any one of claims 1 to 6, characterized in that the mammal is human.

8. The use according to any one of claims 1 to 7, characterized in that the at least one nonpathogenic, hydrogenotrophic, acetogenic bacterial strain is administered in a form which allows it to be active in the colon.

9. The use according to any one of claims 1 to 8, characterized in that said composition containing the at least one nonpathogenic, hydrogenotrophic, acetogenic bacterial strain is administered orally or rectally.

10. The use according to any one of claims 1 to 9, characterized in that the at least one nonpathogenic, hydrogenotrophic, acetogenic bacterial strain is packaged in an anaerobic environment.

11. The use according to any one of claims 1 to 10, characterized in that the composition comprises at least one additive which promotes the activity of the at least one strain in the digestive environment.

12. The use according to any one of claims 1 to 11, characterized in that the composition also comprises at least one other agent active against at least one of the pathologies targeted.

13. The use according to any one of claims 1 to 12, characterized in that the composition also comprises a pharmaceutically acceptable carrier.

18. A method for specifically monitoring a nonpathogenic, hydrogenotrophic, acetogenic bacterial strain, used according to claim 1, in the digestive tract of a mammal, comprising the following steps:

a. a nucleotide sequence (probe) specific for the nonpathogenic, hydrogenotrophic, acetogenic strain the detection of which is desired is defined;

b. said strain is detected and/or quantified by hybridization of the probe with total nucleic acid extracted from the fecal flora, or with the fecal bacteria attached to a slide.

19. A method for producing a nonpathogenic, hydrogenotrophic, acetogenic bacterial strain, for a use according to claim 1, characterized in that it comprises the following steps:

a. the strain is grown on a suitable medium, under conditions of strict anaerobiosis, in the presence of a carbon-based substrate and/or of H₂/CO₂ as energy source;

b. the bacterial cells are recovered;

c. the bacterial cells are packaged according to the pharmaceutical form chosen.

14. A pharmaceutical or food composition, characterized in that it contains at least one nonpathogenic, hydrogenotrophic, acetogenic bacterial strain.

15. The composition according to claim 14, characterized in that the at least one nonpathogenic, hydrogenotrophic, acetogenic bacterial strain belongs to the Ruminococcus, Clostridium or Streptococcus genus.

16. The composition according to claim 15, characterized in that the at least one nonpathogenic, hydrogenotrophic, acetogenic bacterial strain belongs to the species Ruminococcus hydrogenotrophicus.

17. The composition according to any one of claims 14 to 16, characterized in that it comprises at least one additive which promotes the activity of the at least one strain in the digestive environment.